Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With U.S. Navy to Investigate the Use of Oxycyte PFC Emulsion as an Adjunctive Treatment of Complex Infected Wounds and Related Injuries

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) is pleased to report that the U.S. Navy plans to initiate preclinical studies to investigate the potential use of OBI’s proprietary perfluorocarbon emulsion, Oxycyte®, as an intravenously delivered adjunctive treatment for complex infected wounds and related injuries. This research will be conducted under a Cooperative Research and Development Agreement. The primary purpose of the research is to assess the efficacy of Oxycyte for the treatment of infected and/or ischemic wounds. The study protocols and timeline are under development at this time.